PENSACOLA, Fla. – A new ongoing pilot is testing remote monitoring technology from ActiGraph and Clinical Ink in future Bayer clinical trials to improve patient engagement, enhance patient support and discover trends in patient behavior that could help get medicines to them faster and more efficiently.
“Our hopes are to create a better experience for all involved with our clinical trials while enhancing our data collection efforts,” said Michelle Shogren, pharmaceuticals R&D portfolio and operations, at Bayer, in a statement. “By listening to the patient’s voice, we have the ability to improve our study designs of the future and ultimately help patients get the medicines they need.”
The pilot, conducted by Health Innovation Technology Lab, features ActiGraph’s activity monitor, Clinical Ink’s SureSource Engage mobile application and a Bluetooth-enabled weight scale. Phase one of the study was recently completed.
In the pilot, patients wear an activity monitor continuously for and measure their weight. At the end of phase one, the study team collected comprehensive feedback from the participants to understand how they perceived and interacted with the technology and to identify specific areas for improvement.
Improvements for phase two of the study included the use of ActiGraph’s CentrePoint Data Hub, a home-based communication device that helps minimize the burden on participants by passively uploading activity monitor data to a centralized cloud platform via cellular network.